Method 2002.

Methods	Randomised controlled study
Participants	102 women with ovarian cancer after primary therapy (disease status at study entry not described)
Interventions	Intravenous monoclonal antibody (oregovomab ‐ CA‐125): 2 gifts vs 3 gifts vs 6 gifts
Outcomes	Tumour responses Immune response: humoral (Ab2, HAMA), cellular Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Information about the sequence generation process insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Allocation concealment (selection bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding or incomplete blinding, but review authors judge that the outcome is not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Reporting of attrition/exclusions insufficient to permit judgement of ‘low risk’ or ‘high risk'; only abstract available
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available